Bruce F

Bruce F.

location_on

Bethesda, MD & Sarasota, FL, United States

Investment Range

$10,000 - $300,000

calendar_today
person Other
public United States

Professional background

Initially a published scientist (100+publications, NIH grants/study section member) Ph.D. in Microbiology/Immunology. Attorney in FDA regulatory areas - device, drugs, biologics, biotech,...) for 28 years (retired) with leading law firms, Venture Partner, TVM (retired) and now high net worth investor and participant in start-up biomedical companies as Board member, Management Team and fund raiser. Using the experience of counseling large and mid-size and early stage pharma (traditional, biotech, generic,...), as Board member with several drug, vaccine and medical technologies companies in which I have invested

Areas of Expertise

As an Immunologist/microbiologist publishing over 100 publication, I have a good grasp of scientific nuances impacting on biomedical companies, and have used this scientific knowledge in interacting with FDA, Health Canada, EMA, PMDA (Japan) etc. I was on both an NIH study section as a reviewer, then on a NHLI SBIR/STTR review group until 2020. I have spent almost 30 years as a private attorney in the FDA, USDA, EPA,...areas counseling companies developing products - medical/diagnostic devices, traditional/biotech new drugs and generics, biologics, and companies developing biotech products.
As an attorney, I performed FDA due diligence for venture capital groups, and was a consultant/venture Partner to TVM (Muinch/Boston). Retiring from FDA practice I have helped start several biomedical companies, invested in several start-ups, on the Board of several drug, vaccine and medical technologies companies, and been an investor in several early biomedical startups ($10,000-$300,000).

Companies

EP
Ethicann Pharmaceuticals Inc.
Founder

Ethicann Pharmaceuticals (Sarasota/Bethesda MD/Toronto, CN) based specialty pharma company that reformulates approved drugs with safety issues into safer, metered sublingual doses and achieves rapid approvals using abbreviated new drug approval strategies (2025 > Canada, UK, Germany, EU & FDA). Have had successful meetings with FDA and Health Canada to confirm approval strategies. First product to treat MS spasticity only requiring human bioequivalence for new drug approval Canada, UK, Germany & EU; US 505b2 NDA. Using proprietary oral disintegrating tablet (ODT) delivery (Catalent) and ultra-high purity APIs to avoid impurities. www.ethicann-pharma.com . Have just closed $1.5M convertible note, executed license for proprietary Zydis oral disintegrating tablets (ODT) with Catalent, UK. Active fund rasier for Ethicann, will be at JP Morgan Healthcare Conference, talking with investment bankers, VCs and ultra-high net worth investors.

Interests

Industries

Medical & Sciences

Medical & Sciences

Products & Inventions

Products & Inventions

Technology

Technology

Finance

Finance

Stages

Pre-Startup/R&D MVP/Finished Product Achieving Sales Breaking Even Profitable Other

Sectors

No sectors entered yet

Location

Midwest South East West South West North East

Countries

United States Germany United Kingdom Australia

Join our growing network of entrepreneurs and investors

AIN helps investors and entrepreneurs build lasting and profitable relationships to build better businesses and brighter futures.

Loading…
Loading the web debug toolbar…
Attempt #